Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20851567 | 0.79 | F10 (0.41) | F10 | |
| SCHEMBL5657387 | 0.76 | LMNA (0.33) | F10 | |
| Hydrochloric Acid SCHEMBL5655576 | 0.74 | F10 (0.32) | F10 | |
| SCHEMBL18905837 | 0.72 | KCNH2 (0.33) | — | |
| SCHEMBL28391787 | 0.71 | F10 (0.39) | KMT2AF10 | |
| SCHEMBL4404604 | 0.71 | FDPS (0.56) | FDPSMEN1KMT2A | |
| SCHEMBL18912119 | 0.70 | — | — | |
| SCHEMBL8269024 | 0.70 | GRM5 (0.36) | F10 | |
| SCHEMBL18250727 | 0.69 | — | — | |
| SCHEMBL12776032 | 0.68 | CYP1A2 (0.39) | FDPSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | FDPS 972/4885HTR2A 290/4885HTR2C 230/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | FDPS 972/4885HTR2A 290/4885HTR2C 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.